Get the app
US › Healthcare

Lipocine Inc (LPCN)

US · Healthcare · Biotechnology

$2.22+2.78%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$190,099
Revenue YoY
-69.5%
Net profit
$-2.6M
EPS
$-0.32
EPS estimate
$-0.47
Net margin
-1,379.6%

EPS came in at -0.32 against a street estimate of -0.47 — a beat of 31.9%.

Key statistics

Market cap
$18.5M
Forward P/E
5.6
P/B
0.85
Book value
$2.64
EPS (TTM)
$-1.85
52-week high
$12.37
52-week low
$1.81
50-day MA
$2.22
200-day MA
$4.49
Beta
0.47

Analyst view

Analysts rate Lipocine Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders
4.51%
Institutions
36.19%

Largest institutional holders

FundStake
Squadron Capital Management LLC9.82%
Ikarian Capital, LLC6.17%
StemPoint Capital LP3.89%
Eversept Partners, LP3.58%
Rosalind Advisors, Inc.2.69%
Vanguard Capital Management, LLC2.43%
BOOTHBAY FUND MANAGEMENT, LLC1.70%
Seven Fleet Capital Management LP1.52%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lipocine Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.